ManagementBSE · 544619
Sudeep Pharma Ltd
Sudeep Pharma Ltd - 544619 - Announcement under Regulation 30 (LODR)-Change in Management
01 / The disclosure
What the company shared
We wish to inform the changes in the SMP of the Company, arising due to completion of contractual arrangements between the company and Mr. Sendhil Pani, Managing Director of Sudeep Pharma USA Inc., (Wholly Owned Subsidiary of Sudeep Pharma Limited) w.e.f. 2nd October 2026. Kindly take the note of the same.
Exchange-provided summary Company profile
A question for your research
Check the role, effective date, stated reason and succession arrangements.
The evidence
Read the source excerpts
PDF text extraction is queued. The summary above comes from the exchange listing.
Source & verificationView the disclosure trail
- Summary method
- Exchange-provided text; no generated financial figures
- Exchange identifier
- eea2faff-340d-478d-a7b1-2423aa55e338
- First collected
- 5 Oct 2026, 22:51 IST
- PDF extraction
- pending
You’ve reached the end of this disclosure.